y Repligen Corp., Cambridge, Mass., was awarded two U.S. patents _Nos. 5,321,030 and 5,324,731 _ covering novel uses of AM285(cyclocreatine), the company's first small-molecule candidate, andother creatine compounds for antitumor and antiviral therapies.y Ethical Holdings plc, of the United Kingdom, got an approvalnotification on its U.S. patent application covering its core transdermaltechnology.y LifeCell Corp., The Woodlands, Texas, received formal notificationfor allowance of claims for a U.S. patent covering its technology forfreeze-drying transfusable cells.y Martek Biosciences Corp., Columbia, Md., was issued U.S. patentNo. 5,324,658 covering Celtone, its cell growth medium for bacteriaand yeast that uses stable isotope biochemicals derived frommicroalgae.y Immunomedics Inc., Morris Plains, N.J., was issued Canadian patentNo. 1,329,119 covering the use of any cytotoxic agent for treatingcancer, infections, or immunosuppressing a patient for organtransplantation, whereby the agent is combined with a hematopoieticcytokine for preventing, reducing or reversing toxicity to the bloodcells. Also, the European counterpart to the patent emerged from thestatutory period without opposition.
(c) 1997 American Health Consultants. All rights reserved.